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Background: There is an urgent need for biomarkers for the early detection of ovarian cancer (OC). The purpose of this study was to
assess whether changes in serum levels of lecithin-cholesterol acyltransferase (LCAT), sex hormone-binding globulin (SHBG), glucose-
regulated protein, 78 kDa (GRP78), calprotectin and insulin-like growth factor-binding protein 2 (IGFBP2) are observed before clinical
presentation and to assess the performance of these markers alone and in combination with CA125 for early detection.
Methods: This nested case–control study used samples from the United Kingdom Collaborative Trial of Ovarian Cancer Screening
trial. The sample set consisted of 482 serum samples from 49 OC subjects and 31 controls, with serial samples spanning up to 7 years
pre-diagnosis. The set was divided into the following: (I) a discovery set, which included all women with only two samples from each
woman, the first ato14 months and the second at432 months to diagnosis; and (ii) a corroboration set, which included all the serial
samples from the same women spanning the 7-year period. Lecithin-cholesterol acyltransferase, SHBG, GRP78, calprotectin and
IGFBP2 were measured using ELISA. The performance of the markers to detect cancers pre-diagnosis was assessed.
Results: A combined threshold model IGFBP2478.5ngml 1 : LCATo8.831mgml 1 :CA125435Uml 1 outperformed CA125 alone
for the earlier detection of OC. The threshold model was able to identify the most aggressive Type II cancers. In addition, it increased the
lead time by 5–6 months and identified 26% of Type I subjects and 13% of Type II subjects that were not identified by CA125 alone.
Conclusions: Combined biomarker panels (IGFBP2, LCAT and CA125) outperformed CA125 up to 3 years pre-diagnosis,
identifying cancers missed by CA125, providing increased diagnostic lead times for Type I and Type II OC. The model identified
more aggressive Type II cancers, with women crossing the threshold dying earlier, indicating that these markers can improve on
the sensitivity of CA125 alone for the early detection of OC.
Ovarian cancer (OC) has the highest mortality rate of all the
gynaecological cancers with an estimated 15 500 deaths in the
United States in 2012 alone (Siegel et al, 2012). This is due to its
typically late diagnosis, with 5-year survival rates of 5% in those
diagnosed at Stage IV. If diagnosed early, at stage I, the 5-year
survival rate rises to490% (CRUK, 2014). There is an unmet need
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for diagnostic tests that enable earlier diagnosis, which would
increase survival.
Ovarian cancer can be classified into Type I (more indolent
tumours lacking mutations in TP53) and Type II (aggressive
cancers displaying TP53 mutations in 480% of cases), which
account for most of the OC mortality) (Kurman and Shih, 2010).
Serum CA125 is the only biomarker currently used to triage and
monitor patients (Jacobs and Bast, 1989), with a threshold of
35Uml 1 triggering referral to a gynaecological oncologist
(Cramer et al, 2011). However, CA125 elevation is not unique to
OC, as it is also raised during menstruation, pregnancy and
endometriosis, and it is only elevated in B50% of early stage
cancers (Jacobs and Bast, 1989). Extended combinations of
biomarkers should offer higher discriminatory power. A putative
panel of biomarkers, identified at OC diagnosis, from the Prostate,
Lung, Colorectal and Ovarian cancer study (Cramer et al, 2011)
proved unable to detect OC in pre-clinical samples (Zhu et al, 2011),
suggesting putative biomarkers were elevated at clinical presentation
but not present earlier in the natural history of the disease.
The prospectively collected serum sample set generated during
the United Kingdom Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS) (Menon et al, 2008; Menon et al, 2009a;
Menon et al, 2015) offers the possibility of discovering biomarkers
in pre-clinical serum samples. A previous study by the authors’
using isobaric tags (iTRAQ) identified 90 proteins differentially
expressed between OC cases and controls. A second targeted mass
spectrometry analysis of twenty of these putative biomarkers led to
the successful validation of Protein Z as a potential early detection
biomarker for OC from the UKCTOCS sample set (Russell et al,
2016). Here, a further five putative biomarkers identified in this
previous work, lecithin-cholesterol acyltransferase (LCAT), insu-
lin-like growth factor-binding protein 2 (IGFBP2), sex hormone-
binding globulin (SHBG), glucose-regulated protein, 78 kDa
(GRP78) and calprotectin (uniprot accession numbers P04180,
P18065, P04278, P11021 and complexed P05109 and P06702),
were investigated for their utility in OC screening. Insulin-like
growth factor-binding protein 2 and SHBG are both hormone-
binding proteins that have previously been implicated in OC
(Flyvbjerg et al, 1997; Baron-Hay et al, 2004; Nolen and Lokshin,
2012; Gharwan et al, 2015). Lecithin-cholesterol acyltransferase has
previously been shown to be downregulated in breast cancer at
diagnosis (Hilal Kiziltunc and Askin, 2013). Calprotectin is an
antibacterial cytosolic protein found most abundantly in neutro-
phils and upregulation of serum levels occur during inflammation
(Striz and Trebichavsky, 2004); it has previously been shown to be
upregulated in plasma of women with OC (Odegaard et al, 2008).
Glucose-regulated protein, 78 kDa is a glucose-regulated protein,
which controls protective mechanisms during stress; it has been
shown to be upregulated in malignant breast lesions (Fernandez
et al, 2000) and via association with STMN1 to promote metastasis
in such tumours (Kuang et al, 2016).
We therefore sought to investigate the performance of this panel
in combination with CA125 for early diagnosis of OC and their
ability to identify the most aggressive subtypes in a nested case–
control study within UKCTOCS.
MATERIALS AND METHODS
Serum samples. United Kingdom Collaborative Trial of Ovarian
Cancer Screening (International Standard Randomised Controlled
Trial, number ISRCTN22488978; ClinicalTrials.gov NCT0005
8032) is a randomised controlled trial of OC screening in the
general population, approved by the UK North West Multicentre
Research Ethics Committees (North West MREC 00/8/34). Trial
design, including eligibility criteria and details of recruitment has
been described in detail elsewhere (Menon et al, 2008; Menon et al,
2009a; Menon et al, 2015). All women provided written
informed consent for use of their samples in secondary studies.
The current biomarker discovery study was approved by the Joint
UCL/UCLH Committees on the Ethics of Human Research
(Committee A) (Reference Number 05/Q0505/57). Full details
of sample acquisition, transport and storage and CA125 quanti-
fication in the sample set have been published previously (Menon
et al, 2009a).
The serum set investigated here comprised eighty women; 49
women with OC, 30 Type II and 19 Type I (of which 10 were
borderline and as with previous studies were grouped with Type I
for analysis (Shih and Kurman, 2004; Wu et al, 2013; Russell et al,
2016); 31 control samples were selected from women in the study,
who had no diagnosis of a cancer during follow-up and were
matched by age, collection centre and collection date to the Type II
samples. This set contained all of the invasive OC samples available
that had serial samples spanning less than 14 months to diagnosis
right through to greater than 32 months and up to 84 months to
diagnosis. Multiple serial samples were available from these 80
women so the full sample set comprised 482 individual samples
spanning up to seven years prior to diagnosis (time to diagnosis, tDx).
The set was divided into the following: (i) a discovery set, which
comprised two samples per woman, one at o14 months and the
other at 432 months tDx; and (ii) a corroboration set, which
comprised the additional serial samples from the same women
spanning a 7-year period tDx.
Serum measurements. ELISA assays for IGFBP2 and LCAT
(Cloud Clone Corp., Wuhan, Hubei, China), SHBG (R&D Systems,
Abingdon, UK), GRP78 (Enzo Life Sciences, Exeter, UK) and
calprotectin (Biolegend, San Diego, CA, USA) were performed in
duplicate using commercial kits following manufacturers’
instructions.
The mean coefficients of variance for duplicate analysis for each
assay were as follows: IGFBP2: 8.1%; LCAT: 8.4%; SHBG: 7.4%;
GRP78: 3.1%; and calprotectin: 4.5%. Serum CA125 levels were
available as previously described (Menon et al, 2009a).
Statistical analysis. All analysis was performed using the R
environment for statistical analysis. The Mann–Whitney test was
used to assess significance of differences. The Fisher’s exact test was
used to assess significance of categorical data. Correlations were
assessed using Pearson’s product moment. Logic-rule-based
threshold models were constructed to investigate the biomarkers
discriminatory power (O’Brien et al, 2015). Differences in
sensitivity between models were assessed with McNemar’s test.
The areas under the curve of receiver operating characteristics
curves were calculated for threshold models. Significance of lead
time improvement was calculated with a paired t-test. All tests
were two tailed and those with P-values o0.05 were considered
statistically significant.
RESULTS
Study set characteristics. The baseline characteristics of the study
participants and tumour characteristics have previously been
reported (Russell et al, 2016) and are provided as Supplementary
Data (Supplementary Tables S1 and S2). Subjects’ BMI, current
HRT and oral contraceptive pill use were recorded at recruitment,
and HRT use and smoking recorded in the first follow-up
questionnaires sent to all participants 3–5 years post randomisa-
tion. None of these factors correlated with OC diagnosis.
Serum levels of IGFBP2, SHBG, LCAT, GRP78, calprotectin and
CA125 in the discovery set. In the discovery set, IGFBP2, SHBG,
LCAT, GRP78 and calprotectin were quantified using commercial
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ELISA kits, whereas CA125 levels were available from the main
UKCTOCS trial database (Menon et al, 2009a). Protein expression
was log transformed and scaled to unit variance allowing
direct comparison between markers (Figure 1). The expression
of these markers at o14 and 432 months to diagnosis
were analysed separately for Type I and Type II OC cases
(to ascertain whether the proteins were potential subtype-specific
early detection markers). The results were then combined and
analysed to ascertain their potential as pan OC early detection
biomarkers.
Insulin-like growth factor-binding protein 2 showed no
significant change in the Type I or Type II individual analysis
but did show upregulation in the pan OC analysiso14 months to
diagnosis (P¼ 0.054). Sex hormone-binding globulin serum levels
were significantly downregulated in the Type-I (P¼ 0.018) and the
pan OC (P¼ 0.033) 432 months to diagnosis. Although LCAT
showed significant downregulation in Type-I (P¼ 0.0044) and pan
OC (P¼ 0.0096) o14 months to diagnosis. Neither GRP78 nor
calprotectin showed significant regulation compared with controls.
CA125 showed significant upregulation in serum for Type II
(P¼ 7.4 10 8) cases ato14 months to diagnosis. In addition, it
showed significant upregulation for both Type I o14 months
(P¼ 0.0013) and 432 months (P¼ 0.026), and for pan OC o14
months (P¼ 2.3 10 7) and 432 months (P¼ 0.048) in these
samples.
Correlation of biomarker expression with epidemiological
factors. Correlation of biomarker expression with epidemiological
factors was investigated within the discovery set. BMI and
contraceptive pill use (‘Have you ever taken the oral contraceptive
pill?—yes or no’) assessed at recruitment and age-at-sample were
significantly correlated only with SHBG (P¼ 0.009, P¼ 0.034 and
P¼ 0.043, respectively). HRT use at recruitment (‘Are you
currently on hormone replacement therapy (HRT)?—yes or no’)
was correlated with IGFBP2 (P¼ 0.01) and SHBG (P¼ 0.03)
expression but HRT use at follow up (‘Are you currently taking
HRT?’—yes or no) showed no correlations with expression. Contra-
ceptive pill use at recruitment was correlated with SHBG (P¼ 0.034).
Smoking assessed at follow up (‘Have you ever been a smoker?—yes
or no’) was not correlated with any biomarker expression.
Combined analysis of discovery and corroboration set. IGBP2,
LCAT and SHBG were taken forward for further analysis and were
quantified in the additional samples of the corroboration set.
Protein expression was log transformed and scaled to unit variance
for comparison. As with the discovery set protein expression was
analysed separately for Type I and Type II OC cases and the results
then combined to investigate their potential as pan OC early
detection biomarkers.
There are two potential applications for biomarker panels in the
early detection of OC. One is their potential use as aids in clinical
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Figure 1. Box plot showing putative biomarker expression in the discovery sample set at 432 months tDx and o14 months tDx. The whisker
limits represent the 5th and 95th percentiles; the box limits represent interquartile range; the closest point in the notches (4o) of the box plot
represents the median and the span from the bottom to the top of the notch is 95% confidence interval (for significant values between cases and
controls it can be seen that these do not overlap). Significant P-values are indicated on the plot. (For this initial triage the value for IGFBP2 is shown
as it is close to the cutoff value).
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‘triage’ for symptomatic/high-risk patients. Analysis of the
biomarker levels from a single blood sample, with no temporal
information, at primary care centres could be used to ascertain the
risk of OC. This is investigated in Figure 2, where the levels of the
potential biomarkers are compared to control levels. The second
application would be as part of a ‘screening’ programme. Here, the
levels of the potential markers would be followed temporally to
determine if they indicated early disease initiation and progression,
this is outlined in Figure 3.
Insulin-like growth factor-binding protein 2, SHBG and CA125
levels display differential expression for OC triage. The levels of
IGBP2, LCAT, SHBG and CA125 were compared directly with
those of the control population in all samples (Figure 2). Insulin-
like growth factor-binding protein 2 was significantly upregulated
in Type-I (P¼ 0.024) and in the pan OC (P¼ 0.045). SHBG was
significantly downregulated in Type-I (P¼ 0.012) and Type-II
(P¼ 0.012), and in the pan OC (P¼ 0.0035). Lecithin-cholesterol
acyltransferase displayed no differential expression at this stage of
the analysis. CA125 was significantly upregulated in Type-I
(P¼ 3.4 10 13) and Type-II (P¼ 4.1 10 8), and in the pan
OC (P¼ 5.7 10 13).
Insulin-like growth factor-binding protein 2, SHBG, LCAT and
CA125 display differential expression pre-diagnosis for screen-
ing. The levels of all of the biomarkers were compared directly
with those of the control population at yearly intervals, from
diagnosis up to 4 years pre-diagnosis after which all time points
44 years tDx were grouped together (Figure 3). Insulin-like
growth factor-binding protein 2 was significantly upregulated: in
Type-I samples ato1 year tDx (P¼ 0.0045) and for pan OC ato1
year tDx (P¼ 0.014). Sex hormone-binding globulin was signifi-
cantly downregulated in Type-I samples at 2–3 years tDx
(P¼ 0.027) and at the same time point in Type-II (P¼ 0.042)
and in pan OC (P¼ 0.012). Lecithin-cholesterol acyltransferase
showed significant downregulation in OC with respect to controls
in Type-I samples o1 year tDx (P¼ 0.036) and upregulation at
44 years tDx (P¼ 0.019).
CA125 showed significant upregulation in Type I samples ato1
year (P¼ 5.4 10 7), 1–2 (P¼ 0.023), 2–3 (P¼ 0.0064) and 44
years tDx (P¼ 0.00039). In Type II cases it displayed significant
upregulation o1 year tDx, whereas in the pan OC comparison it
demonstrated upregulationo1 (P¼ 8.7 10 12), 1–2 (P¼ 0.023)
and 44 years tDx (P¼ 0.0046).
Triage. Sensitivities for detection of OC using the putative
biomarkers were assessed by applying selected cutoffs and an
‘OR’ rule (O’Brien et al, 2015) for the expression of each
biomarker alone and in combination with each other and CA125
(Table 1), improvements in sensitivity have been highlighted
in grey.
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Figure 2. Comparison of putative biomarker expression in pre-diagnosis sets with no division by tDx. The whisker limits represent the 5th and
95th percentiles; the box limits represent interquartile range; the closest point in the notches (4o) of the box plot represents the median and the
span from the bottom to the top of the notch is 95% confidence interval (for significant values between cases and controls it can be seen that these
do not overlap). Significant P-values are indicated on the plot.
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Threshold models demonstrate improved sensitivity for OC.
The selected thresholds were LCAT: o8.831 mgml 1; SHBG:
o16.1 nmol l 1; and IGFBP2: 478.5 ngml 1 set to give a 5%
false positive rate. The threshold for CA125 was taken as the level
at which a woman would be referred to a gynaecological oncologist
35Uml 1 (Cramer et al, 2011). With a small decrease in
specificity, the combined panels all yielded dramatically increased
sensitivity over CA125 alone for both Type I and Type II OC.
Screening. The putative biomarkers were again assessed, at yearly
intervals, by applying selected cutoffs and an ‘OR’ rule (O’Brien
et al, 2015) for the expression of each biomarker alone and in
combination with each other and CA125 (Supplementary
Table S3); statistically significant improvements in sensitivity are
shown in orange.
Individual models outperform CA125. Although individual
threshold models (IGBFP2/SHBG/ LCAT) displayed increased
sensitivity over CA125 alone for various time points for Type I,
Type II and Pan OC, they were not statistically significant.
Individual markers combined with CA125 models outperform
CA125 alone. The IGBFP2 : CA125 threshold model outper-
formed CA125 (Supplementary Table S3) in Type I OC at 44
year tDx where its sensitivity was 45 times that of CA125;
however, the specificity was slightly lower. For Type II patients it
outperformed CA125 at 1–2 years tDx where sensitivity tripled. It
also outperformed CA125 in terms of sensitivity at 44 years tDx,
where its sensitivity quadrupled but with slightly lower specificity.
In the pan OC analysis, it outperformed CA125 at o1 and at 1–2
years tDx. It also outperformed CA125 in terms of sensitivity at
2–3 and 44 tDx, but with a slight decrease in specificity.
The SHBG : CA125 model did not significantly outperform
CA125 (Supplementary Table S3) in the Type I, Type II or pan OC
analysis.
The LCAT : CA125 model only out performed CA125 for pan
OC at o1 year tDx.
Combination biomarker models outperform CA125 alone.
Figure 4 shows the performance, in terms of sensitivity, of the
multiple marker combinations in conjunction with CA125.
The plots demonstrate an improvement in sensitivity for all the
combination panels compared with CA125 alone for Type I, Type
II and Pan OC.
The SHBG : IGFBP2 : CA125 model most strikingly significantly
outperformed CA125 alone in Type I OC at o1 and 44years to
diagnosis. Although for Type II it significantly outperformed
CA125 at 1–2 and 44 years tDx. In the pan OC analysis, it also
outperformed CA125 in terms of sensitivity at all times points,
with only 3–4 years tDx not displaying significance.
The LCAT : SHBG : CA125 model significantly outperformed
CA125, for Type I at o1 year tDx. For Type II patients, it
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outperformed CA125 at all time points, but with no statistical
significance. In the pan OC analysis, it significantly outperformed
CA125 at 44, 1–2 and o1 year to tDx.
The IGFBP2 : LCAT : CA125 model significantly outperformed
CA125 in Type I OC at 44, 1–2 and o1 year tDx. For Type II
patients, it significantly outperformed CA125 at44 and 1–2 years
to tDx. In the pan OC analysis, it also outperformed CA125 in
terms of sensitivity at all times points, with only 3–4 years tDx not
displaying significance.
The combination of all markers (LCAT : SHBG : IGFBP2 :
CA125) model significantly outperformed CA125 (Figure 4) in
Type I OC at 44, 1–2 and o1 years tDx. For Type II patients, it
significantly outperformed CA125 at 44 and 1–2 years to tDx. In
the pan OC analysis, it also outperformed CA125 in terms of
sensitivity at all times points, with only 3–4 years tDx not
displaying significance.
Although the all marker combination performs well, its
specificity is lowered by the presence of SHBG (Supplementary
Table S3). This means that the IGFBP2 : LCAT : CA125 model
provided the best improvement in performance for the detection of
OC over CA125 alone.
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Lead time estimation. For Type-I OC, 11 women were not
detected by either elevated CA125 or the combined IGFBP2 :
LCAT : CA125 model. Of the remaining eight subjects, five were
detected earlier by this combined model, of which four were not
detected by CA125 alone. For the combined model the mean lead
time was 454 days tDx, whereas for CA125 alone it was 315 days
tDx (P¼ 0.032).
For Type-II OC, 13 women were not detected either by CA125
or combined IGFBP2 : LCAT : CA125 model. Of the remaining 17
women, 4 were detected by the combined model earlier than
CA125 alone and 2 of these were not detected by the CA125
threshold at all. For this combined model, the mean lead time was
272 days tDx, whereas for CA125 alone the lead time was 165 days
tDx. Combining all OC together, gave a mean lead time for CA125
alone of 213 days and the IGFBP2 : LCAT : CA125 model of 330
days (P¼ 0.014), a difference of 107 days equating to a four month
improvement over CA125 alone.
Prognosis. An additional question that can be asked is does this
IGFBP2 : LCAT : CA125 threshold model provide us with informa-
tion on the aggressiveness of the OCs. This was investigated via
Kaplan–Meier analysis, using the time from diagnosis to death.
Plotting survival curves for the Type II patients that breach this
threshold versus those that do not (Figure 5) confirmed a
significant difference in survival curves; those patients that breach
the IGFBP2 : LCAT : CA125 threshold model (Figure 5A) have a
lower survival (P¼ 0.047) than those that do not. This is directly
attributable to the threshold model as Figure 5B shows that in
survival curves based on CA125 alone there is no difference in
survival between those who cross the CA125 threshold and those
who do not (P¼ 0.254) confirming IGFBP2 : LCAT : CA125 as a
prognostic panel.
DISCUSSION
Despite intensive efforts over the past three decades to improve
treatment (both surgery and chemotherapy) for the disease,
there is still a poor outcome for women diagnosed with OC. In
2014, 7378 women in the United Kingdom were diagnosed with
OC and there were 4128 deaths. The majority of OC cases are
diagnosed at late stage, with a 5-year survival rate of o23% for
Stage III and IV cancers (Nolen and Lokshin, 2012; Hu¨ttenhain
et al, 2012; CRUK, 2014). When detected, early prognosis is much
better, with490% of women diagnosed at Stage I surviving 5 years
(CRUK, 2014). There is therefore a significant need to develop
strategies, which can detect OC early. Serum biomarkers are
attractive targets for early detection and indeed the serum marker
CA125 has been widely used in screening trials for OC (Moore
et al, 2009; Menon et al, 2009b; Cramer et al, 2011; Skates, 2012;
Bristow et al, 2013; Drescher et al, 2013). However, CA125 has
limitations of specificity for OC (Jacobs and Bast, 1989). Thus,
there is a real need for the identification and development of
biomarkers capable of improving on or complementing CA125 in
order to enable the earlier detection of OC.
This is the first study to have investigated the expression of
putative OC biomarkers IGFBP2, LCAT, SHBG, GRP78 and
calprotectin in prospectively collected pre-clinical samples,
enabling an unbiased assessment of how these markers alter
during OC progression.
The most effective biomarker panel was a combination of
IGFBP2 : LCAT : CA125. This panel identified 26% of Type I
subjects and 13% of Type II subjects not identified by the
CA125 threshold alone. This panel also displayed an increased
lead time of 5–6 months for Type I and 3–4 months for Type II
OC. It is important to note when considering the above
lead time results that women enrolled on the UKCTOCS study
were on average diagnosed between 1 and 2 years earlier
than is typical in the unscreened population, giving potential lead
times of 2–3 years offering a significant window for clinical
intervention.
Kaplan–Meier plots also demonstrate that this threshold panel
is discriminatory for more aggressive OC as Type II subjects who
breach the threshold model have a lower survival rate than Type II
patients who do not.
Following initial analysis of IGFBP2, LCAT, SHBG, GRP78 and
calprotectin within our discovery set IGFBP2, LCAT and SHBG,
were taken forward as potential markers for OC and further
analysed within our corroboration set. Markers were analysed over
a 7 years pre-diagnosis period and binned into yearly time
windows (Figure 3). IGFBP2 displayed significant upregulation at
o1 year tDx for the Type I and Pan OC analysis. SHBG displayed
significant downregulation in Type I, Type II and Pan OC
at 2–3 years to diagnosis, LCAT showed significant down-
regulation in Type I OC at o1 year tDx and significant
upregulation at 44 years tDx. However, none of these markers
outperformed CA125.
In order to ascertain whether the putative biomarkers could be
constructed into a panel with CA125 that would improve on
CA125 alone, for the early detection of OC, threshold models were
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Figure 5. Survival curves. (A) for the combined threshold model (IGFBP2 : LCAT :CA125), (B) for CA125, using time to death post diagnosis. The
dotted black line represents Type II patients who did not breach the threshold. The solid black line represents Type II patients with samples that
breached the threshold.
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investigated. These models were constructed for all members of the
biomarker panel and combinations tested against CA125 alone.
The combination of CA125 and IGBP2 improved the sensitivity for
detection of OC for both Type I and Type II at 44 years and for
Type II at 1–2 pre-diagnosis. The combination of CA125 and
LCAT showed improvements against CA125 alone in theo1 year
time range for Pan OC.
At the next level, CA125 was combined with two markers
IGBP2 : SHBG, LCAT : SHBG and IGBP2 : LCAT. The most
striking feature of the two panels containing SHBG is that it has
a deleterious effect on the specificity of the models.
The most effective biomarker panel was IGFBP2 : LCAT :
CA125; this panel outperformed CA125 in terms of sensitivity at
nearly all time points measured for the Type I and Type II cancers,
with at least a doubling in the sensitivity of the panel at 0–2 years’
pre-diagnosis for Type I OC and a greater than tripling in
sensitivity for Type II at 1–2 and44 years tDx. For Type I OC, 11
women were not detected by elevated CA125 or the combined
IGFBP2 : LCAT : CA125 threshold. Of the remaining eight subjects,
five were detected earlier by the combined threshold, of which four
were not detected by CA125 alone. For the combined threshold,
the mean lead time was 454 days tDx, whereas for CA125 alone it
was 315 days tDx (P¼ 0.032).
For Type II OC, 13 women were not detected either by CA125
or combined IGFBP2 : LCAT : CA125 thresholds. Of the remaining
17 women, 4 were detected by the combined threshold earlier than
CA125 alone; of these, 2 were not detected by the CA125 threshold
at all. For the combined threshold model the mean lead time was
272 days tDx, whereas for CA125 alone the lead time was 165 days
tDx. Combining all OC together gave a mean lead time for CA125
alone of 213 days and the combined model of 330 days (P¼ 0.014),
a difference of 107 days equating to a 4-month improvement over
CA125 alone.
This is the first study to have investigated the expression of
putative OC biomarkers IGFBP2, LCAT and SHBG in prospec-
tively collected pre-clinical samples. Treated as single markers,
these proteins offered low sensitivities, but in a combined threshold
model they were able to correctly identify OC in samples that did
not breach the CA125 threshold, improving on the sensitivity of
CA125 alone and identifying cases it missed. In addition, they
provide an increased lead time of several months in the detection
of OC over CA125 alone and importantly identified the more
aggressive Type II cancers. Before their utility in a clinical setting
can be assessed, these panels will need to be further validated in
larger cohorts. However, the threshold models generated within
this study demonstrate the potential of these biomarkers in
improving the sensitivity and detection of OC as part of a panel
incorporating CA125.
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